February update 2024

by CannerGrow
Posted on Februar 10, 2024 09:00

Dear CannerGrow Community,

We would like to provide you with an update on recent developments. We are aware that you have not heard from us this year, but this is due to our intense focus on various projects. We are actively engaged in contract negotiations, GMP validations, regulatory discussions, and other critical tasks to achieve our goals in the coming weeks. Since our inception in 2017, we have made significant progress thanks to your tremendous support. Today, we are proud to announce that we operate the largest indoor production facility in Europe.

What's new?

We are expanding our team in the board of directors and human resources departments. This week, we have already held two important meetings with shareholders. Currently, we are actively recruiting 8 new team members, including 3 C-level positions, to further position ourselves successfully in the Big Pharma market. For further details regarding our operations in both Frauenbrunnen and Solothurn, please refer to the ROADMAP section in your dashboard, as it provides the most up-to-date information. Additionally, we have strengthened our quality assurance team with an individual boasting over 30 years of experience in the GMP and Big Pharma sectors. Currently, 4 full-time employees are dedicated to GMP validations, supported by our consultants in this field.

It is essential to emphasize the significance of this work as even minor adjustments can have significant impacts. For instance, the change in floor color in our cleanroom, as depicted in the attached image, was necessitated by a crucial meeting before Christmas involving representatives from the Canton of Bern authorities, our GMP experts, and our internal quality assurance team. It was determined that while the surface must exhibit a specific level of roughness to ensure workplace safety, it must also be as smooth as possible to meet GMP requirements and prevent the accumulation of dust and particles. After extensive discussions and reviews of our SOPs and regulations, the floor was accordingly adjusted.


At the end of 2023, we parted ways with our previous KYC provider and implemented a new KYC process, requiring us to gather new data. This led to a significant surge in inquiries, which we are working tirelessly to address promptly. We appreciate your understanding if there are delays in responding to your inquiries as we prioritize addressing all outstanding requests.


We ceased plant sales at the end of 2022 and eliminated several positions throughout 2023 to reduce our monthly expenses. Unfortunately, 80% of inquiries are addressed in the FAQ section and under the Roadmap, consuming significant time to manage everything on time. Please note that you can track progress and scheduling through the "Roadmap" tab in your dashboard, providing an overview of planned developments and project milestones. Additionally, under the "Help" tab, you will find FAQs regularly updated with new information.

Closing remarks:

We appreciate your patience amid any delays, and we are confident that your wait will be rewarded. We are proud to have created something truly unique with our state-of-the-art production and extensive GMP facility, setting a standard that few in Europe can match.

We look forward to sharing further insights in the next blog post, featuring some vibrant medical cannabis plants. Stay tuned for our next blog post and the unveiling of our new chapter.

Thank you for your continued support and trust!
Your CannerGrow Team